Insmed Inc. (NASDAQ:INSM) shares are rising. A report surfaced that Sanofi is exploring an offer for the rare-disease drug developer.
- Insmed stock is gaining positive traction. Why is INSM stock trading higher?
Insmed Stock Rises On Sanofi Takeover Report
Two respiratory medicines of Insmed’s have won approval and reached the market. The company’s Brinsupri drug addresses bronchiectasis, while Arikayce targets a chronic lung condition, and a third treatment still in development is aimed at interstitial lung disease and idiopathic pulmonary fibrosis, Bloomberg reported.
Bloomberg reported Thursday that Sanofi, under CEO Belen Garijo, is eyeing a deal that would rank among the largest in pharma in years. Neither Sanofi nor Insmed would comment.
Paying the typical 30% premium over Insmed’s unaffected share price would cost Sanofi roughly €31 billion ($34 billion). Jefferies analyst Michael Leuchten said that sum is not beyond Sanofi’s reach, and Sanofi’s chief financial officer has hinted the company has the capacity for a large purchase.
Dupixent, a blockbuster for skin conditions and asthma, has powered Sanofi’s growth, yet its patent protection is set to expire, and investors want a stronger pipeline. Garijo’s strategy leans on building out commercial products and growing in categories including rare diseases.
However, risks remain. A number of shareholders and analysts cautioned that the expected price could strain Sanofi’s finances.
INSM Shares Are Rising
INSM Price Action: Insmed shares were up 1.07% at $146.01 at the time of publication on Friday, according to Benzinga Pro.
Image: Shutterstock
